Press release
RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists | Researchmoz
Researchmoz added Most up-to-date research on "RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists" to its huge collection of research reports."RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma Antagonists and Agonists"
Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but difficult-to-drug target. More than 30 companies are active in drug discovery and development. Technology companies with expertise in discovery of drugs targeting nuclear hormone receptors are preferred partners of Big Pharma and Biotech companies if they have identified novel scaffolds of RORgamma antagonists. More than ten such technology-pharma partnerships have been founded and already lead to first successes. Three RORgamma antagonists (inverse agonists) are already in clinical development and more to follow in 2016 and thereafter.
The report explains the scientific rationale for discovering antagonists of RORgamma for treatment of autoimmune and inflammatory diseases, but also of agonists of RORgamma for treatment of cancer. Clinical as well as non-clinical data for target validation of RORgamma are provided. Lead and up-side indications for development including the key product profile are discussed. Potential safety concerns for novel RORgamma modulators were identified.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=556098
Drug discovery approaches of technology and pharmaceutical companies are shown regarding strategies in partnering as well as in technologies applied for structure-based drug discovery. Based on the experience in the past, estimates of the required time from start of a discovery program of RORgamma modulators until entry into human studies are calculated. The competitive landscape of RORgamma modulator development and discovery projects is analyzed and the profiles of companies elaborated, separately for unpartnered technology or pharmaceutical companies and for partnerships between technology and pharmaceutical companies.
The report provides an understanding of:
- The target RORgamma
- Clinical and non-clinical target validation
- Clinical lead and up-side indications
- Drug discovery strategies and technologies
- Commercial value of drug discovery collaborations
- R&D timelines from start of screening to first-in-human studies
- Competitive landscape of RORgamma antagonists
- Agonists of RORgamma for cancer
- Profiles of unpartnered technology companies and lead projects
- R&D Partnerships and their discovery approaches and lead molecules
- Unpartnered pharmaceutical companies and their programs
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=556098
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists | Researchmoz here
News-ID: 396637 • Views: …
More Releases from RORgamma Modulators
RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma an …
Researchmoz added Most up-to-date research on "RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists" to its huge collection of research reports.
Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but difficult-to-drug target. More than 30 companies are active in drug discovery and development. Technology companies with expertise in discovery of drugs targeting nuclear hormone receptors are preferred partners of Big Pharma and Biotech…
More Releases for Clinical
Miami Clinical Research Sets the Standard for Clinical Trials
Miami Clinical Research, a frontrunner in the world of clinical trials and medical research, has emerged as the prime choice for global corporate pharmaceutical giants. With a deep understanding of the complexities of medical studies, the organization champions the crucial role of research in the evolution of transformative therapeutic interventions.
Miami, FL - Renowned as a first-rate center for professional medical exploration, Miami Clinical Research [https://miamiclinicalresearch.com] boasts state-of-the-art facilities, advanced technologies,…
E-Clinical Solutions Market: Revolutionizing Healthcare and Clinical Trials
Introduction
The e-Clinical solutions market has become a pivotal component of the healthcare and pharmaceutical industries. E-Clinical solutions refer to a set of software, tools, and platforms designed to streamline clinical trials and healthcare management. These solutions include electronic data capture (EDC), clinical trial management systems (CTMS), laboratory information management systems (LIMS), and other integrated tools that improve the efficiency, accuracy, and speed of clinical trials and healthcare services. The primary…
E-Clinical Solutions Market: Revolutionizing Clinical Trials
The e-clinical solutions market has experienced significant growth in recent years, driven by the increasing complexity of clinical trials and the need for efficient, accurate, and compliant data management. E-clinical solutions provide a comprehensive suite of tools and technologies to streamline clinical trial processes, accelerate drug development, and improve patient outcomes.
Market Size and Growth
The global e-clinical solutions market is estimated to be worth billions of dollars, with a significant portion…
Clinical Trials Management System Market Optimizing Clinical Trials: The Crucial …
Clinical Trials Management System Market to reach over USD 5.06 billion by the year 2031- Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Clinical Trials Management System Market Size, Share & Trends Analysis Report By Solution Type (Enterprise and Site based), By Delivery Mode (Web & Cloud-based, On-premise), By Component (Software, Services), By End-user (Pharmaceutical and Biotechnology Firms, Medical…
Clinical Research and Clinical Trials Summit
Clinical Research 2019 has been designed in an interdisciplinary manner with a multitude of tracks to choose from every segment and provides you with a unique opportunity to meet up with peers from both industry and academia and establish a scientific network between them. We cordially invite all concerned people to come join us at our event and make it successful by your participation.
This is the premier interdisciplinary forum for…
E-Clinical Trial Solutions Market To Accelerating Clinical Development Technolog …
The study of the "Global e-Clinical Trial Solutions Market" provides the market size information and market trends along with the factors and parameters impacting it in both short and long term. The study ensures a 360° view, bringing out the complete key insights of the industry.
The Global e-Clinical Trial Solutions Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the e-Clinical…
